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Background: The presence of lipids in alveolar macrophages (AMs) may impair their phagocytic
response, and determine airway inflammation and obstruction.
Objective: To determine the factors such as severity of asthma, chronic cough, airway inflam-
mation and obesity that may influence the presence of lipids in lung macrophages.
Methods: Bronchoalveolar lavage fluid (BALF) was obtained from 38 asthmatics (21 severe and
17 mild/moderate), 16 subjects with chronic cough and 11 healthy control subjects. The pres-
ence of lipids in macrophages was detected using an Oil-red-O stain and an index of lipid-laden
macrophages (LLMI) was obtained.
Results: LLMI scores were higher in healthy subjects (median 48 [IQR 10e61]) and the severe
asthma group (37 [11.5e61]) compared to mild/moderate asthmatics (7 [0.5e37]; p < 0.05
each). Subjects reporting a history of gastro-oesophageal reflux disease (GORD) had higher
LLMI values (41.5 [11.3e138] versus 13 [0e39.3], p Z 0.02). There was no significant correla-
tion between LLMI and chronic cough, BAL cell differential counts, FEV1, FEV1/FVC or body
mass index (BMI).
Conclusions: The reduced LLMI in mild/moderate asthma may be related to lower incidence of
GORD. However, this was not related to the degree of airflow obstruction, obesity or airway
inflammation.
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Abbreviations
ATS American Thoracic Society
Ams alveolar macrophages
BDP beclomethasone diproprionate
BDR bronchodilator reversibility
BMI body mass index
BALF bronchoalveolar lavage fluid
FEV1 forced expiratory volume in 1 s
FVC forced vital capacity
IgE immunoglobulin E
LLMI lipid-laden macrophage index
LLAM lipid-laden alveolar macrophage
PC20FEV1 provocative concentration of
methacholine causing a 20% fall in
PFC pulmonary foam cell
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Macrophages are found in most tissues including the lungs
and airways where they play an important role in immune
surveillance. They are responsible for the phagocytosis and
endocytosis of dying cells and pathogens. Sputum macro-
phages from asthmatic subjects exhibit a phagocytic
response that is inversely correlated with sputum eosino-
philia and positively correlated with FEV1 and PC20FEV1 [1].
This suggests that decreased phagocytosis relates to airway
inflammation and asthma severity. In contrast, sputum-
derived macrophages from asthmatic patients with no
sputum eosinophilia display impaired efferocytosis of
apoptotic bronchial epithelial cells [2]. In addition, a
reduced phagocytic response to Staphylococcus aureus [3]
in macrophages from children with severe asthma has
been related to the presence of oxidative stress as assessed
by glutathione oxidation [4].
Alveolar macrophages (AMs) that become laden with
lipid (predominantly cholesterol) are termed pulmonary
foam cells or lipid-laden alveolar macrophages (LLAMs).
These macrophages are more likely to undergo the process
of programmed cell death and exhibit impaired phagocy-
tosis [5], which may play an important pathogenic role in
asthma. Furthermore, markers of lipid peroxidation
measured in plasma are increased in asthma subjects [6]
whilst erythrocytes and platelets exhibit alterations in
membrane fatty acid composition [7].
A high fat content diet and the administration of a lipid
emulsion in rats has been associated with the formation of
LLAMs, leading to the view that the lungs may be a po-
tential route of lipid excretion. However, it remains unclear
whether such cells are derived from AMs ingesting lipids in
the alveoli or from lipid-laden blood monocytes that
migrate to the alveoli [8].
Lipid accumulation in alveolar macrophages appears to
occur primarily through the phagocytosis of external lipo-
proteins. This process may be secondary to endogenous
sources, such as lipoid pneumonia; where the presence of
bronchial obstruction, chronic lung infection or a lipid
storage disorder results in the accumulation of LLAMs; or anexogenous source, for example following aspiration or
inhalation of lipid [9]. There are other factors which have
been associated with an increase in LLAM formation. These
include gastroesophageal reflux disease (GORD) [10,11],
hypoxia [12] and iatrogenic causes, whereby drugs such as
amiodarone, fluoxetine, and gentamicin containing a
cationic amphiphilic structure can induce cellular phos-
pholiposis through a dose-dependent process involving the
inhibition of lysosomal phospholipase activity and accu-
mulation of lamellar bodies [13,14]. In addition, macro-
phages have been shown to internalise and degrade
surfactant lipids and surfactant protein A (SP-A) in vitro,
suggesting a role for AMs in surfactant clearance [15]. Other
factors such as obesity and cholesterol may also influence
lipid-laden macrophage formation, but their role has not
yet been established.
The aim of this study was to explore the relationship
between the presence of LLAMs, chronic cough and asthma
severity in a cohort of patients with mild/moderate and
severe asthma. In addition, we determined whether
obesity, the presence of GORD, lung inflammation or the
degree of airflow obstruction influenced the accumulation
of intracellular lipids.
Methods
Patients
Patients were recruited from our Asthma Clinic and through
advertisement, and underwent a screening visit. Those with
significant respiratory or inflammatory co-morbidities and
those requiring treatment for a respiratory tract infection
within the preceding four weeks were excluded. Healthy
subjects had no smoking history and no history of respira-
tory or cardiac disease. All subjects underwent a broncho-
scopic procedure with bronchoalveolar lavage.
Asthma was based on a physician diagnosis and patients
either had a PC20 methacholine concentration causing a 20%
fall in FEV1 of <8 mg/ml and/or an FEV1 reversibility of
12% of baseline. Severe asthma was defined according to
the American Thoracic Society (ATS) definition of refractory
asthma [16]. Patients who did not fulfil the criteria for se-
vere asthma were classified as non-severe asthmatics and
they were taking 1000 mcg of inhaled beclomethasone
dipropionate (BDP) or equivalent per day.
Patients with chronic cough were recruited from a
specialist cough clinic at our hospital and all subjects re-
ported a dry persistent cough for at least 8 weeks duration.
All subjects had been investigated with a standard protocol
to exclude a diagnosis of asthma or other respiratory
disease.
Ethical approval was obtained from the West London 3
and the Brompton, Harefield and NHLI Research Ethics
Committees (11/H0706/4 and 08/H0708/29).
Fibreoptic bronchoscopy and bronchoalveolar
lavage
Sixty-seven patients (21 severe asthma, 19 mild/moderate
asthma, 16 patients with chronic cough, and 11 healthy
subjects) underwent fibreoptic bronchoscopy with
Figure 1 Determination of lipid-laden macrophage index
(LLMI). BAL cytospins were stained with Oil-Red-O. AMs were
graded by the amount of lipid in the cytoplasm staining red.
Cells were scored from 0 to 4: 0Z no opacification, 1Z up to
¼ opacified, 2Z ¼ to ½ opacified, 3Z ½ to 3/4 opacified, and
4Z totally opacified. The panels show examples of each score.
LLMI was reported as the sum of the scores of 100 cells giving a
potential score range of 0e400.
Lipid-laden macrophages 73bronchoalveolar lavage (BAL). These were performed
under sedation according to standard clinical practice at
the Royal Brompton Hospital. BAL was performed from a
segment of the right middle lobe (RML). The bronchoscope
was wedged and warmed aliquots of buffered normal sa-
line were installed (50 ml  4, total 200 ml) and imme-
diately aspirated through the bronchoscope by gentle
suction.
BAL fluid was centrifuged (500  g for 10 min), washed
with Hanks’ balanced salt solution (HBSS) and the cell
pellet re-suspended in culture media (RPMI with 0.5% fetal
calf serum, antibiotics and L-glutamine) to a density of
w0.5  106 macrophages/ml. Cytospins were stained with
REASTAIN Quick-Diff kit (Reagena International Oy Ltd,
Finland) and a cell differential count was performed.
Measurement of lipids in macrophages
We used the lipid-laden macrophage index (LLMI) to quan-
tify lipid accumulation in AMs. Slides were air-dried and
then stored at 80 C. They were then stained with Oil-
Red-O (SigmaeAldrich Ltd, UK) to enable scoring and LLMI
calculated by grading the amount of intracellular Oil-Red-O
positive particles per 100 AMs (Fig. 1). Intracellular lipid
was evaluated using a modified version of that proposed by
Corwin and Irwin [17,18]. Cells were scored from 0 to 4
whereby 0 Z no opacification, 1 Z up to ¼ opacified,
2 Z ¼ to ½ opacified, 3 Z ½ to 3/4 opacified, and
4 Z totally opacified (Fig. 1). The LLMI was calculated by
the sum of the scores of 100 cells giving a potential range
from 0 to 400. The person who measured the LLMI was not
aware of clinical findings.
Statistical analysis
Categorical variables were reported as percentages and
comparisons done using the chiesquare or Fisher’s exact
test. Numerical variables were reported as mean (SD) or
median (IQR) and comparisons done using ManneWhitney
test or Kruskal Wallis test. Statistical significance was
defined as p < 0.05. Logistic regression was used to assess
the predictive factors for GORD.
Results
Patient characteristics
Two patients were excluded from subsequent analysis due
to poor quality of the staining. Significant differences were
seen between groups in terms of inhaled and oral cortico-
steroid use, FEV1 % predicted and FEV1/FVC ratio (Table 1).
The severe asthma group exhibited greater bronchodilator
reversibility and lower PC20. Both asthmatic groups were
more likely to be atopic than the chronic cough and healthy
control group (81% and 87.5% compared to 33.3%, 27.3%
respectively; p < 0.0005). Sixteen patients (28.6%) re-
ported a history of GORD of whom 14 were taking medica-
tion with proton pump inhibitors. A greater history of GORD
and PPI use was noted in the severe asthma (40% and 42.1%
respectively) and chronic cough (41.7% and 44.4%) groupscompared to the mild/moderate asthma (21.4% and 13.3%)
and healthy control (none reported) groups.
BAL cell differential counts were similar between all the
groups with an increase in eosinophils noted in the mild/
moderate group (p < 0.05). A higher neutrophil percentage
in BALF was noted in the severe group (median 3.4%, [IQR
0.9e7.3]), but this did not reach statistical significance
(Table 2).
Lipid-laden macrophage index in different groups
A wide range was seen in the severe asthma (0e246) and
chronic cough (0e297) groups. The distribution of LLMI by
diagnoses can be seen in Fig. 2. The mild/moderate asth-
matic group had the lowest LLMI (median, 7; IQR 0.5e37)
with a significant difference noted versus the severe
asthma (median, 37; IQR 11.5e61, p < 0.05) and healthy
Table 1 Demographics.
N Healthy subjects Chronic cough Mild/moderate asthma Severe asthma p value
11 16 17 21
Age (years) 35.6  13.9 43.1  12.8 43.7  14.6 43.8  12.5 0.34
M/F 8/3 5/11 11/6 11/10 0.13
ICS (BDP equivalent [mg]) 0 0 (0e500) 200 (0e600) 1600 (1600e4000) <0.0001
Oral steroid (mg), (n) 0 (0) 0 (0) 0 (0) 10 (0e20), 14
BMI 26.9 (25.6e32.4) 25.5 (23.9e27.4) 24.9 (21.1e30.3) 28.4 (24.6e33.5) 0.33
Smoking
Current 0 1 0 0 0.45
Ex 1 1 0 3
Never 10 13 17 18
FEV1 % 104.8 (98.2e108.0) 87.7 (83.6e100.4) 84.9 (69.8e88.9) 74.9 (60.6e84.0) <0.0001
FEV1/FVC % 81.6 (75.6e86.1) 79.0 (75.3e84.4) 69.9 (67.7e74.2) 64.7 (54.5e72.9) <0.0001
BDR (n) 1.4  2.3 (6) NA 13.9  8.2 (14) 22.8  13.8 (17) 0.0002
PC20 (n) >16 (11) >16 (3) 2.3  2.5 (14) 0.88  0.6 (5) <0.0001
Atopic (%)a 3 (27.3) 4 (33.3) 14 (87.5) 17 (81.0) 0.0005
IgE kU/l 73.5 (21e126.3) 58.5 (16e137.5) 151.0 (63e268.5) 184 (49.5e615.5) 0.06
GORD (%) 0 (0) 6 (50) 2 (14.3) 8 (42.1) 0.02
PPI (%) 0 (0) 4 (44.4) 2 (12.5) 8 (42.1) 0.03
Data are presented as mean  SD or median (IQR). Between group comparisons for continuous variables were made using KruskaleWallis
test and for catergorial variables using c2 exact testing.
BMI, body mass index.
BDR, bronchodilator response.
BDP eq, beclomethasone dipropionate equivalent.
PPI, proton pump inhibitor.
a The data presented are for subjects with either a positive RAST or skin prick test.
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difference was noted between the other groups. A similar
pattern was seen when the total number of cells (score out
of 100) staining positive were analysed. The healthy (me-
dian 23; IQR 9e36) and severe (17.5; 5.5e48.5) were higher
than the mild/moderate (7; 0.5e14) and chronic cough (7;
2e21) groups.
No significant associations were noted between BALF
cell differential and the LLMI for the entire cohort or for
individual groups. One chronic cough patient with an LLMI
of 297 had a BAL neutrophilia of 69% although, in two other
cases where the LLMI was greater than 200, there was no
neutrophilia.GORD
Six of the top eight subjects with the highest LLMI scores,
including the top four, reported a history of GORD. TheTable 2 Differential cell counts in bronchoalveolar lavage.
N Healthy subjects Chronic cough
11 15
Neutrophils % 1.5 (0e1.8) 1.7 (0.9e5.2)
Eosinophils % 0.3 (0e0.8) 0.2 (0e1.0)
Macrophages % 90.2 (55.8e95.8) 90.4 (64.1e94.3)
Lymphocytes % 7.5 (2.0e39.8) 5.7 (4.0e24.7)median LLMI score was higher in the GORD group (median
41.5 [IQR, 11.3e138] versus 12.5 [2.3e35.3]) compared to
those who did not (p < 0.05) (Fig. 3). Univariate logistic
analysis (Table 3) showed a significant association between
the presence of GORD and an LLMI score of 60.
Other associations
There was no association between FEV1 and LLMI in indi-
vidual groups or all subjects grouped together. There were
no differences in LLMI according to eosinophilia, age, BMI,
gender or atopy.
Discussion
We have found that LLMI scores were lower in mild/mod-
erate asthmatics compared to the severe asthmatics and
healthy controls. The difference between the two asthmaMild/moderate asthma Severe asthma p value
16 18
1.2 (0.5e2.6) 3.4 (0.9e7.3) 0.15
1.4 (0.3e6.4) 0.6 (0e3.8) 0.03
87.0 (73.8e93.2) 87.4 (75.5e93.3) 0.98
5.4 (2.1e12.0) 5.6 (2.0e12.9) 0.84
Figure 2 Distribution of lipid-laden macrophage index (LLMI)
in normal, patients with chronic cough and in mild-moderate and
severe asthma patients. Median scores are shown. *p < 0.05.
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in the severe group (42.1% versus 14.3%). Another potential
explanation relates to increased levels of oxidised or gly-
cated low-density lipoproteins (LDL) seen in asthma
[19,20]. This has been suggested as a modulator of
inflammation and results in LLM formation via macrophage
scavenger receptor recognition [21]. The use of oral corti-
costeroids (OCS) is another potential confounding factor. 14
(66.7%) of the severe asthma cohort were on maintenance
oral corticosteroid therapy. However, subanalysis of the
cohort according to OCS use showed no significant differ-
ences in LLMI scores.
Patients with chronic cough had a lower LLMI compared
to the severe asthma group and healthy controls, although
this did not reach statistical significance. LLMI has been
evaluated as a marker of chronic aspiration in chronic
cough. A study of 30 consecutive adults presenting to a
tertiary referral centre with chronic cough found that there
was no significant difference in LLMI scores when compared
to 20 asymptomatic adults [24].Figure 3 Lipid-laden macrophage index (LLMI) (expressed on
log10 scale) in patients with and without a history of gastro-
esophageal reflux disease (GORD). Median scores are shown.
*p < 0.05.The higher scores seen in the healthy cohort are harder
to explain given that no GORD was reported. This supports
the view that lipid accumulation is a normal process
including the ingestion of lipids endogenously present
within the alveolar space, such as lung surfactant [15].
Another explanation may be related to micro-aspiration
and the fact that no subjects in the healthy cohort were
taking PPIs. LLMI scores were highly variable and there was
considerable overlap between groups. Despite previous
reports associating LLMI with BALF neutrophilia [22] and
airflow obstruction [23], we did not find an association in
this cohort.
There was a correlation between the presence of GORD
and LLMI, with greater scores in the symptomatic group.
The association between aspiration and LLMI has been
previously evaluated in children with some studies report-
ing a positive correlation [18,25] and suggesting that
particular cut-off values may be a useful diagnostic test
[26]. However, other studies have failed to confirm that
LLMI, measured in lavage fluid or sputum, is an indicator of
GORD [18,27], highlighting a lack of specificity to detect
reflux-related respiratory disease [28]. In adults, LLMI has
been proposed as a marker for aspiration pneumonia [10].
In cystic fibrosis patients post lung transplantation, it may
be a useful method of assessing response to Nissen fundo-
plication [29] and a score of >150 was found to have a
sensitivity of 82.3% and a specificity of 76.4% correlating
with an abnormal 24-h pH test in these lung transplant re-
cipients [30].
LLMI measured in macrophages obtained from sputum
samples has been correlated to oropharyngeal reflux [11].
However, other studies have failed to confirm this [31] and
the use of LLMI in induced sputum is limited in smokers;
where the presence of inclusions from cigarette smoke
within the cytoplasm, resulting from the phagocytosis of
cigarette smoke particulates, increases the LLMI score
[32].
Although this study has identified an association be-
tween GORD and LLMI, there are some limitations. We
relied on self-reported GORD and did not use objective
measures such as validated questionnaires or a 24-h pH
probe. A study incorporating objective measures and
selecting a more symptomatic cohort would be better
placed to examine this potential association. LLMI calcu-
lation is time-consuming and a simpler semi-quantitative
method of calculating alveolar lipid content has been sug-
gested [23] which appear to produce similar results [33]. In
addition, the repeatability of LLMI scores in individuals is
not known. Further studies, incorporating repeat bron-
choscopies, are required to establish whether this simpler
method could replace the LLMI and provide information on
individual variability. We have compared asthma and
chronic cough patients to a cohort of healthy subjects.
Furthermore, LLMI may fluctuate over time depending on
factors such as hyperlipidaemia, BMI and micro-aspiration.
LLMI should be correlated to the underlying disease pro-
cess and co-morbidities that may influence the presence of
lipid-laden macrophages.
This is the first time LLMI has been assessed in asthma.
Although no correlation was seen with BALF neutrophils or
with the degree of airways obstruction, there was a strong
association with GORD.
Table 3 Univariate Logistic Regression of predictive fac-
tors for presence of gastro-oesophageal reflux disease
(GORD).
Predicting factors Odds ratio 95% CI p value
Age 1.01 0.97e1.05 NS
Gender 1.07 0.34e3.39 NS
FEV1 (% pred) 0.99 0.96e1.02 NS
BAL eos (%) 1.31 0.28e6.02 NS
BAL neut (%) 0.78 0.28e2.91 NS
LLMI
0e20 1.0
21e59 2.64 0.64e10.91 0.18
60 8.7 1.79e42.3 0.007
CI Z confidence interval, NS Z non-significant.
76 D. Gibeon et al.Contributions
Study conception and design e all authors. Data abstraction
and statistical analysis e DG, AS, WB, CR, JP. The manu-
script was written by DG and KFC. Manuscript revision and
final approval e all authors.Conflicts of interest
DG, JZ, AS, WB, CR, JS, JPR, JH, AMG, PKB and KFC have no
conflicts of interest to report with respect to this study.Acknowledgements
This project was supported by the NIHR Respiratory Disease
Biomedical Research Unit at the Royal Brompton and
Harefield NHS Foundation Trust and Imperial College
London. DG was supported through the UBIOPRED project
funded by the Innovative Medicine Initiative.References
[1] Alexis NE, Soukup J, Nierkens S, Becker S. Association be-
tween airway hyperreactivity and bronchial macrophage
dysfunction in individuals with mild asthma. Am J Physiol Lung
Cell Mol Physiol 2001 Feb;280(2):L369e75.
[2] Simpson JL, Gibson PG, Yang IA, Upham J, James A,
Reynolds PN, et al. Impaired macrophage phagocytosis in non-
eosinophilic asthma. Clin Exp Allergy 2013 Jan;43(1):29e35.
[3] Fitzpatrick AM, Holguin F, Teague WG, Brown LA. Alveolar
macrophage phagocytosis is impaired in children with poorly
controlled asthma. J Allergy Clin Immunol 2008 Jun;121(6).
1372-8, 1378.
[4] Fitzpatrick AM, Teague WG, Burwell L, Brown MS, Brown LA.
Glutathione oxidation is associated with airway macrophage
functional impairment in children with severe asthma. Pediatr
Res 2011 Feb;69(2):154e9.
[5] Schrijvers DM, De Meyer GR, Kockx MM, Herman AG,
Martinet W. Phagocytosis of apoptotic cells by macrophages is
impaired in atherosclerosis. Arterioscler Thromb Vasc Biol
2005 Jun;25(6):1256e61.[6] Rahman I, Morrison D, Donaldson K, MacNee W. Systemic
oxidative stress in asthma, COPD, and smokers. Am J Respir
Crit Care Med 1996 Oct;154(4 Pt 1):1055e60.
[7] De CJ, Hernandez-Hernandez A, Rodriguez MC, Sardina JL,
Llanillo M, Sanchez-Yague J. Comparison of changes in
erythrocyte and platelet phospholipid and fatty acid compo-
sition and protein oxidation in chronic obstructive pulmonary
disease and asthma. Platelets 2007 Feb;18(1):43e51.
[8] Shibuya K, Tajima M, Yamate J, Saitoh T, Sannai S. Genesis of
pulmonary foam cells in rats with diet-induced hyper beta-
lipoproteinaemia. Int J Exp Pathol 1991 Aug;72(4):423e35.
[9] Hadda V, Khilnani GC. Lipoid pneumonia: an overview. Expert
Rev Respir Med 2010 Dec;4(6):799e807.
[10] Adams R, Ruffin R, Campbell D. The value of the lipid-laden
macrophage index in the assessment of aspiration pneu-
monia. Aust N Z J Med 1997 Oct;27(5):550e3.
[11] Parameswaran K, Anvari M, Efthimiadis A, Kamada D,
Hargreave FE, Allen CJ. Lipid-laden macrophages in induced
sputum are a marker of oropharyngeal reflux and possible
gastric aspiration. Eur Respir J 2000 Dec;16(6):1119e22.
[12] Bostrom P, Magnusson B, Svensson PA, Wiklund O, Boren J,
Carlsson LM, et al. Hypoxia converts human macrophages into
triglyceride-loaded foam cells. Arterioscler Thromb Vasc Biol
2006 Aug;26(8):1871e6.
[13] Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholi-
pidosis: issues and future directions. Expert Opin Drug Saf
2006 Jul;5(4):567e83.
[14] Jacobson W, Stewart S, Gresham GA, Goddard MJ. Effect of
amiodarone on the lung shown by polarized light microscopy.
Arch Pathol Lab Med 1997 Dec;121(12):1269e71.
[15] Wright JR, Youmans DC. Degradation of surfactant lipids and
surfactant protein A by alveolar macrophages in vitro. Am J
Physiol 1995 May;268(5 Pt 1):L772e80.
[16] Proceedings of the ATS workshop on refractory asthma: cur-
rent understanding, recommendations, and unanswered
questions. Am J Respir Crit Care Med 2001;162:2341e51.
[17] Corwin RW, Irwin RS. The lipid-laden alveolar macrophage as a
marker of aspiration in parenchymal lung disease. Am Rev
Respir Dis 1985 Sep;132(3):576e81.
[18] Colombo JL, Hallberg TK. Recurrent aspiration in children:
lipid-laden alveolar macrophage quantitation. Pediatr Pul-
monol 1987 Mar;3(2):86e9.
[19] Schunemann HJ, Muti P, Freudenheim JL, Armstrong D,
Browne R, Klocke RA, et al. Oxidative stress and lung function.
Am J Epidemiol 1997 Dec;146(11):939e48.
[20] Sedgwick JB, Hwang YS, Gerbyshak HA, Kita H, Busse WW.
Oxidized low-density lipoprotein activates migration and
degranulation of human granulocytes. Am J Respir Cell Mol
Biol 2003 Dec;29(6):702e9.
[21] Brown BE, Nobecourt E, Zeng J, Jenkins AJ, Rye KA, Davies MJ.
Apolipoprotein A-I glycation by glucose and reactive aldehydes
alters phospholipid affinity but not cholesterol export from
lipid-laden macrophages. PLoS One 2013 May;8(5):e65430.
[22] Sacco O, Silvestri M, Sabatini F, Sale R, Moscato G, Pignatti P,
et al. IL-8 and airway neutrophilia in children with gastro-
esophageal reflux and asthma-like symptoms. Respir Med 2006
Feb;100(2):307e15.
[23] Kazachkov MY, Muhlebach MS, Livasy CA, Noah TL. Lipid-laden
macrophage index and inflammation in bronchoalveolar
lavage fluids in children. Eur Respir J 2001 Nov;18(5):790e5.
[24] Carney IK, Gibson PG, Murree-Allen K, Saltos N, Olson LG,
Hensley MJ. A systematic evaluation of mechanisms in chronic
cough. Am J Respir Crit Care Med 1997 Jul;156(1):211e6.
[25] Bauer ML, Lyrene RK. Chronic aspiration in children: evalua-
tion of the lipid-laden macrophage index. Pediatr Pulmonol
1999 Aug;28(2):94e100.
[26] Furuya ME, Moreno-Cordova V, Ramirez-Figueroa JL,
Vargas MH, Ramon-Garcia G, Ramirez-San Juan DH. Cutoff
Lipid-laden macrophages 77value of lipid-laden alveolar macrophages for diagnosing
aspiration in infants and children. Pediatr Pulmonol 2007 May;
42(5):452e7.
[27] Kitz R, Boehles HJ, Rosewich M, Rose MA. Lipid-laden
alveolar macrophages and pH monitoring in gastroesopha-
geal reflux-related respiratory symptoms. Pulm Med 2012;
2012:673637.
[28] Rosen R, Fritz J, Nurko A, Simon D, Nurko S. Lipid-laden
macrophage index is not an indicator of gastroesophageal
reflux-related respiratory disease in children. Pediatrics 2008
Apr;121(4):e879e84.
[29] Hayes Jr D, Kirkby SS, McCoy K, Mansour HM, Khosravi M,
Strawbridge H, Tobias JD. Reduction of lipid-laden macrophage
index after laparoscopic Nissen fundoplication in cystic fibrosis
patients after lung transplantation. Clin Trasnplant 2013 Sep;
27(1):121e5.[30] Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B,
Silverman S. Risk factors and costs associated with an asthma
attack. Thorax 2000 Jan;55(1):19e24.
[31] Koksal D, Ozkan B, Simsek C, Koksal AS, Agackyran Y, Sasmaz N.
Lipid-laden alveolarmacrophage index in sputum is not useful in
the differential diagnosis of pulmonary symptoms secondary to
gastroesophageal reflux. Arch Med Res 2005 Sep;36(5):485e9.
[32] Wilson AM, Nair P, Hargreave FE, Efthimiadis AE, Anvari M,
Allen CJ. Lipid and smoker’s inclusions in sputum macrophages
in patients with airway diseases. Respir Med 2011 Nov;105(11):
1691e5.
[33] Ding Y, Simpson PM, Schellhase DE, Tryka AF, Ding L,
Parham DM. Limited reliability of lipid-laden macrophage
index restricts its use as a test for pulmonary aspiration:
comparison with a simple semiquantitative assay. Pediatr Dev
Pathol 2002 Nov;5(6):551e8.
